ACB
Price
$4.88
Change
-$0.07 (-1.41%)
Updated
Sep 26, 12:55 PM (EDT)
Capitalization
279.62M
41 days until earnings call
SBFM
Price
$1.52
Change
-$0.04 (-2.56%)
Updated
Sep 25 closing price
Capitalization
6.93M
46 days until earnings call
Interact to see
Advertisement

ACB vs SBFM

Header iconACB vs SBFM Comparison
Open Charts ACB vs SBFMBanner chart's image
Aurora Cannabis
Price$4.88
Change-$0.07 (-1.41%)
Volume$600
Capitalization279.62M
Sunshine Biopharma
Price$1.52
Change-$0.04 (-2.56%)
Volume$72.88K
Capitalization6.93M
ACB vs SBFM Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. SBFM commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and SBFM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ACB: $4.95 vs. SBFM: $1.52)
Brand notoriety: ACB: Notable vs. SBFM: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 53% vs. SBFM: 143%
Market capitalization -- ACB: $279.62M vs. SBFM: $6.93M
ACB [@Pharmaceuticals: Generic] is valued at $279.62M. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.93M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACB and SBFM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 6 TA indicator(s) are bullish while SBFM’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 6 bullish, 2 bearish.
  • SBFM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ACB is a better buy in the short-term than SBFM.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -4.44% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was +3.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.81%. For the same industry, the average monthly price growth was +25.12%, and the average quarterly price growth was +68.21%.

Reported Earning Dates

ACB is expected to report earnings on Nov 06, 2025.

SBFM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.81% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($280M) has a higher market cap than SBFM($6.93M). ACB has higher P/E ratio than SBFM: ACB (19.44) vs SBFM (0.00). ACB YTD gains are higher at: 16.471 vs. SBFM (-49.333). ACB has higher annual earnings (EBITDA): 26.6M vs. SBFM (-6.19M). ACB has more cash in the bank: 140M vs. SBFM (10.3M). SBFM has less debt than ACB: SBFM (929K) vs ACB (102M). ACB has higher revenues than SBFM: ACB (358M) vs SBFM (36.3M).
ACBSBFMACB / SBFM
Capitalization280M6.93M4,043%
EBITDA26.6M-6.19M-429%
Gain YTD16.471-49.333-33%
P/E Ratio19.440.001,930,449%
Revenue358M36.3M986%
Total Cash140M10.3M1,359%
Total Debt102M929K10,980%
FUNDAMENTALS RATINGS
ACB vs SBFM: Fundamental Ratings
ACB
SBFM
OUTLOOK RATING
1..100
6916
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
5061
P/E GROWTH RATING
1..100
9084
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (40) in the null industry is in the same range as ACB (58) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

SBFM's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as SBFM (96) in the null industry. This means that ACB’s stock grew similarly to SBFM’s over the last 12 months.

ACB's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as SBFM (61) in the null industry. This means that ACB’s stock grew similarly to SBFM’s over the last 12 months.

SBFM's P/E Growth Rating (84) in the null industry is in the same range as ACB (90) in the Pharmaceuticals Other industry. This means that SBFM’s stock grew similarly to ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBSBFM
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DUOL313.4912.32
+4.09%
Duolingo
AQB1.65-0.04
-2.37%
AquaBounty Technologies
ASIX19.09-0.52
-2.65%
AdvanSix
CPRX19.13-0.57
-2.89%
Catalyst Pharmaceuticals
LIDR2.39-0.09
-3.63%
AEye

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-4.44%
SNDL - ACB
65%
Loosely correlated
-4.28%
CGC - ACB
64%
Loosely correlated
-3.52%
OGI - ACB
62%
Loosely correlated
-3.31%
CRON - ACB
54%
Loosely correlated
-2.58%
TLRY - ACB
54%
Loosely correlated
-5.56%
More

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-2.56%
ELAN - SBFM
28%
Poorly correlated
+0.91%
TLRY - SBFM
27%
Poorly correlated
-5.56%
LFCR - SBFM
25%
Poorly correlated
-3.47%
CGC - SBFM
25%
Poorly correlated
-3.52%
ACB - SBFM
24%
Poorly correlated
-4.44%
More